GREENER Pharmaceuticals for More Sustainable Healthcare

Research output: Journal contributionsScientific review articlesResearch

Standard

GREENER Pharmaceuticals for More Sustainable Healthcare. / Moermond, Caroline T.A.; Puhlmann, Neele; Brown, A. Ross et al.
In: Environmental Science and Technology Letters, Vol. 9, No. 9, 13.09.2022, p. 699-705.

Research output: Journal contributionsScientific review articlesResearch

Harvard

APA

Vancouver

Moermond CTA, Puhlmann N, Brown AR, Owen SF, Ryan J, Snape J et al. GREENER Pharmaceuticals for More Sustainable Healthcare. Environmental Science and Technology Letters. 2022 Sept 13;9(9):699-705. doi: 10.1021/acs.estlett.2c00446

Bibtex

@article{975c6cb3d203434f8317ac63feb30011,
title = "GREENER Pharmaceuticals for More Sustainable Healthcare",
abstract = "Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.",
keywords = "criteria, drug discovery and development, environment, pharmaceuticals, sustainability, water quality, Chemistry",
author = "Moermond, {Caroline T.A.} and Neele Puhlmann and Brown, {A. Ross} and Owen, {Stewart F.} and Jim Ryan and Jason Snape and Venhuis, {Bastiaan J.} and Klaus K{\"u}mmerer",
note = "Publisher Copyright: {\textcopyright} 2022 American Chemical Society.",
year = "2022",
month = sep,
day = "13",
doi = "10.1021/acs.estlett.2c00446",
language = "English",
volume = "9",
pages = "699--705",
journal = "Environmental Science and Technology Letters",
issn = "2328-8930",
publisher = "American Chemical Society",
number = "9",

}

RIS

TY - JOUR

T1 - GREENER Pharmaceuticals for More Sustainable Healthcare

AU - Moermond, Caroline T.A.

AU - Puhlmann, Neele

AU - Brown, A. Ross

AU - Owen, Stewart F.

AU - Ryan, Jim

AU - Snape, Jason

AU - Venhuis, Bastiaan J.

AU - Kümmerer, Klaus

N1 - Publisher Copyright: © 2022 American Chemical Society.

PY - 2022/9/13

Y1 - 2022/9/13

N2 - Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.

AB - Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.

KW - criteria

KW - drug discovery and development

KW - environment

KW - pharmaceuticals

KW - sustainability

KW - water quality

KW - Chemistry

UR - http://www.scopus.com/inward/record.url?scp=85137285228&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/6bb945e1-bc59-31a5-a26f-abde5388cf33/

U2 - 10.1021/acs.estlett.2c00446

DO - 10.1021/acs.estlett.2c00446

M3 - Scientific review articles

C2 - 36118957

AN - SCOPUS:85137285228

VL - 9

SP - 699

EP - 705

JO - Environmental Science and Technology Letters

JF - Environmental Science and Technology Letters

SN - 2328-8930

IS - 9

ER -